$4.03
▼ $-0.28
(-6.50%)
Vol 838K
5
Quality Score
fail
Rev ✗
NI ✗
>IPO ✗
Mkt Cap
$431.1M
ROE
-410.2%
Margin
-20.5%
D/E
2200.40
Beta
1.16
52W
$6–$17
Wall Street Consensus
13 analysts · Apr 20265
Strong Buy
6
Buy
2
Hold
0
Sell
0
Strong Sell
84.6%
Buy Rating
Price Chart
Similar Stocks
Earnings
Beat rate: 50.0%| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Sep 2025 | $-0.18 | $-0.11 | +$0.07 |
| Jun 2025 | $-0.11 | $-0.23 | $-0.12 |
| Mar 2025 | $-0.15 | $-0.15 | $0.00 |
| Dec 2024 | $0.04 | $0.04 | +$0.00 |
Quarterly Revenue & Earnings
| Quarter | 2024-1… | 2025-0… | 2025-0… | 2025-0… | 2025-1… |
|---|---|---|---|---|---|
| Revenue | $78.9M | $68.5M | $69.4M | $69.0M | $90.3M |
| Net Income | -$6.8M | -$18.9M | -$17.1M | -$15.7M | $130K |
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | — | -410.2% | -410.2% | -410.2% | -410.2% | -410.2% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | -24.7% | -22.3% | -22.3% | -22.3% | -20.5% | -20.5% |
| Gross Margin | 65.3% | 66.6% | 66.6% | 66.6% | 65.8% | 65.8% |
| D/E Ratio | — | 2200.40 | 2200.40 | 2200.40 | 2200.40 | 2200.40 |
| Current Ratio | 2.27 | 2.27 | 2.27 | 2.27 | 2.02 | 2.02 |
Key Ratios
ROA (TTM)
-26.2%
P/S (TTM)
1.51
P/B
126.6
EPS (TTM)
$-0.91
CF/Share
$-1.03
Rev Growth 3Y
+38.7%
52W High
$17.12
52W Low
$5.71
$5.71
52-Week Range
$17.12
Financial Health
Free Cash Flow
$10.7M
Net Debt
$101.2M
Cash
$53.8M
Total Debt
$155.0M
As of Dec 31, 2025
How does EOLS compare to Pharmaceuticals peers?
Peer group: Micro-cap Pharmaceuticals (All) · 171 companies
EOLS valuation vs Pharmaceuticals peers
P/E ratio
—
▼
0%
below
peers
(22.4)
vs Peers
vs Industry
Undervalued
P/S ratio
1.5
▼
70%
below
peers
(5.0)
vs Peers
vs Industry
Undervalued
P/B ratio
126.6
▲
5872%
above
peers
(2.1)
vs Peers
vs Industry
Overvalued
Div yield
—
▼
0%
below
peers
(2.0%)
vs Peers
vs Industry
Low yield
EOLS profitability vs Pharmaceuticals peers
ROE
-410.2%
▼
656%
below
peers
(-54.3%)
vs Peers
vs Industry
Weak
Net margin
-20.5%
▲
57%
above
peers
(-47.4%)
vs Peers
vs Industry
Below avg
Gross margin
65.8%
▼
4%
below
peers
(68.3%)
vs Peers
vs Industry
Weak
ROA
-26.2%
▲
30%
above
peers
(-37.4%)
vs Peers
vs Industry
Below avg
EOLS financial health vs Pharmaceuticals peers
D/E ratio
2200.4
▲
142783%
above
peers
(1.5)
vs Peers
vs Industry
High debt
Current ratio
2.0
▼
40%
below
peers
(3.4)
vs Peers
vs Industry
Low liquidity
Beta
1.2
▲
23%
above
peers
(0.9)
vs Peers
vs Industry
More volatile
EOLS fundamentals radar
EOLS
Peer median
Industry
EOLS profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio
EOLS vs peers: key metrics
Latest News
No related news yet